Stem cell therapy in China: which conditions are approved, and where

A published list rather than a sales pitch — twenty licensed cell and gene technologies at one zone in Hainan, the six newest with the hospital each landed at, and what to do when your condition is not among them.

The short answer

Stem cell therapy in China is legal, narrow and—unusually for this category—enumerable. It is not something you buy because you want to feel younger. It is a licensed medical treatment for a named disease, delivered for the most part inside one place: the Boao Lecheng International Medical Tourism Pilot Zone on the east coast of Hainan. The zone does not leave the question to inference. It publishes what it has licensed, which hospital may deliver it, and to whom.

As of the most recent batch, that published record runs to twenty cell and gene technologies across five batches, with 784 recorded patient uses in total. Each entry names an indication and the hospital licensed to perform it. The span runs from a cell vaccine against EB virus infection at one end to a gene therapy for RPE65-related inherited retinal dystrophy at the other, with mesenchymal stem cell and immune cell products filling most of the middle.

So the question most people arrive with—can I get stem cell therapy in China?, or, put the other way, where do I go for stem cell treatment in China?—resolves into a lookup rather than a negotiation. Is your diagnosis on the list? If it is, there is a hospital in the zone licensed to treat it, and the next step is your records rather than your calendar. If it is not, the remaining routes are a clinical trial, the zone's imported-drug pathway, or an honest no. That is the whole shape of it, and the rest of this page is the detail.

What “approved” means on this list, and what it does not

One paragraph of law, because the full version has its own page. Since State Council Order No. 818 came into force on 1 May 2026, cell and gene products in China are regulated as medical treatment for named conditions: a filed indication, written inclusion and exclusion criteria, a staging requirement, a defined course. Legality is decided per indication, not per clinic—the same umbilical cord cells licensed for one disease at one hospital are not licensed for a different disease at the hospital next door. Is stem cell therapy legal in China? is the canonical explanation of what the order changed and how to read a licence.

The narrower point worth making here is what a zone listing is. These are new clinical technologies approved for a named hospital inside the pilot zone, published together with the institution that will deliver them. That is not the same thing as a national marketing authorisation for a medicine, and anyone presenting it as one is overselling. It is, however, a great deal more than the usual position in this field, which is a clinic's own assurance that what it sells is permitted. Here there is a public record with your condition either in it or not.

What the published list actually covers

Across the five batches, the indications that have been licensed cluster into four groups, and seeing them grouped tells you more about the programme than any individual entry.

The number that deserves more attention than the list itself is 784 cumulative patient uses. Spread across twenty technologies and five years of batches, that is a small, deliberate clinical programme. It is not an industry, it is not a production line, and it is a useful corrective to the impression—common in English-language coverage of this subject—that China is treating stem cell therapy at scale. The volume is modest because the gate is real.

The fifth batch, in detail

The six technologies most recently added were announced at the third Boao Lecheng stem cell conference, held on 22 March 2026, and published in the usual form: indication, technology, delivering hospital. They are worth reading one by one, because the pattern in them is the single most informative thing on this page.

Read it sideways and three things fall out. First, four of the six are immune cell therapies, not stem cell therapies. The category noun almost everyone searches is stem cell, and the direction the zone is actually moving in is immunotherapy—NK cells and dendritic cells, given as an adjunct in cancer care. If that is your situation, what NK cell therapy is and which immune cell therapies are licensed in China are the pages that matter, not this one.

Second, the two stem cell entries both treat organ failure—a decompensated liver, a pancreas that is no longer answering its drugs. Neither is given to a well person. The type 2 diabetes filing is the most interesting entry on the list for anyone reading it from a longevity angle, because metabolic disease is the closest the licensed frame has yet come to the things the longevity market sells. It is still a disease filing. It still requires a diagnosis, a failure of conventional treatment, and a specialist who agrees.

Third, the dosing detail is in the filing. Weekly for three weeks; cell number by body weight; three to six sessions. These are not marketing descriptions, they are the course as approved, and they are the kind of specificity you should expect to be given rather than have to extract.

Which cell is which

Four different products are wearing one phrase on this list, and the differences are not cosmetic.

One consequence of that granularity is worth stating plainly: a product being licensed tells you nothing about a different product from the same family. Cells are not a substance with a single safety and efficacy profile, and “stem cells are approved in China” is a sentence with no useful content.

Where this happens, and why it is one place

Every technology above landed at a hospital inside Boao Lecheng, a medical special zone on Hainan's east coast where rules that apply across the rest of the mainland are relaxed in defined ways—imported drugs and devices licensed elsewhere may be used before national approval, real-world data gathered there can feed national registration, and cell and gene technologies may be approved as new clinical technologies for named institutions. The pilot zone explained covers how it came to exist and what it can and cannot do.

Within the zone, allocation is hospital by hospital. Shulan (Boao) Hospital holds two of the six newest technologies; Ciming Boao International Hospital, West China Lecheng Hospital of Sichuan University, Boao Super Hospital and Ruijin Hainan Hospital hold one each. This is the detail most summaries drop, and it is the one that decides where you would physically go. Hainan's 30-day visa-free entry covers the trip itself for most nationalities, and planning a trip to Hainan handles flights, timing and what to bring.

If your condition is not on the list

This is the more common case, and it deserves a straight answer rather than a soft one. There are three legitimate routes and one trap.

And if you are well

Most people reading a page like this one are not holding a diagnosis. They are in their fifties, functioning, tired in a way that annoys them, and wondering whether the thing they have read about is available to them. The answer is no for the cells and yes for a good deal else, and the distinction is worth getting right rather than blurring.

Because every filed indication names a disease, and ageing is not a diagnosis, stem cell programmes here are paused for longevity-only use. If the screening finds something clinical, or you arrive with a prescription or diagnosis from your own physician, cell therapy proceeds on the ordinary clinical footing—that is not an exception grudgingly made, it is simply what the frame was built for. What is open without any of that is the non-cell half: the mitochondrial and NAD+ protocols, therapeutic plasma exchange, hyperthermia, oxygen and red light, delivered as part of a six-axis medical retreat that starts with a screen rather than with a product. Anti-aging treatment in China is the page that takes that question on directly, and cellular health is the one that explains what is and is not measurable underneath it.

What it costs

Treatment programmes carry no price list, and the reason is the same reason the list of indications is so specific: a hospital quote is built from your own diagnostics, your staging and the course your specialists settle on, not from a menu. The wellness side does have a published figure—the retreat is offered from about $2,700 all in for one guest, covering the four days, the screening battery, the wellness axes your screen selects and the follow-up year, against roughly $36,000 to $58,000 at 2026 rates for a comparable week at an Alpine longevity clinic. What a longevity program in China costs breaks down what that figure includes and what it does not.

How to check any of this yourself

1. Ask which filed project the offer corresponds to. Every licensed technology in the zone has a published description naming its indication. A provider should be able to say which one yours is in a sentence.
2. Ask which hospital. Not “Boao Lecheng”—the zone is several hospitals and the licence sits with one of them.
3. Ask whether this is a licensed technology or a trial. Both are legitimate; they are not the same thing, and conflating them is the most common soft misrepresentation in this field.
4. Ask for the course as filed. Number of infusions, interval, how the dose is set. The fifth-batch entries above show the level of detail that exists on paper.
5. Ask what would disqualify you. Exclusion criteria are part of every filing. A programme that has never declined anyone has not read its own.
6. Ask for the batch release certificate. Viability, identity, sterility, endotoxin. This is a document, not an opinion.

What this page is not claiming

Nothing here is a claim that any of these technologies will work for you, or that a licensed filing is the same thing as proven benefit—several of these indications rest on early evidence, and a zone approval is a permission to treat under conditions rather than a verdict on outcome. Nor is this a current legal register: the list grows by batch and the figures above describe the published record as it stood at the fifth batch, which is why the checks in the section above are addressed to the hospital rather than to this page. Candidacy for any programme is determined by the treating hospital's specialists after full diagnostics.

Frequently asked

Is stem cell therapy legal in China?

Yes, inside a narrow frame. Since State Council Order No. 818 came into force on 1 May 2026, cell and gene products are regulated as medical treatment for named conditions, which means a filed indication, written inclusion and exclusion criteria, a staging requirement and a defined course. The practical effect is that legality is decided per indication rather than per clinic: the same umbilical cord cells that are licensed for one disease at one hospital are not licensed for a different disease at the hospital next door. The Boao Lecheng pilot zone in Hainan is where most licensed delivery happens, because the zone can approve a cell or gene technology as a new clinical technology at a named hospital. Our legality guide is the full explanation of Order 818 and what it changed.

What conditions can be treated with stem cells in China?

The zone publishes the list rather than leaving it to be inferred, and as of the fifth batch it runs to twenty cell and gene technologies in total. Across those five batches the published indications cover arthritis, lung disease, heart failure, decompensated liver cirrhosis, periodontal disease, graft-versus-host disease, type 2 diabetes, inherited eye disease, and a range of solid tumours and blood cancers. Not every one of those is a stem cell product — several are immune cell therapies and one is a gene therapy. The honest way to use the list is as a lookup: if your diagnosis appears on it, there is a named hospital licensed to deliver that technology, and if it does not, no amount of willingness to pay changes the filing.

Where can you get stem cell therapy in China?

Overwhelmingly at the Boao Lecheng International Medical Tourism Pilot Zone on the east coast of Hainan, and within the zone at a specific hospital per technology rather than anywhere in it. The six technologies added in the fifth batch landed at five different hospitals: Shulan (Boao) Hospital took two, and Ciming Boao International Hospital, West China Lecheng Hospital of Sichuan University, Boao Super Hospital and Ruijin Hainan Hospital took one each. That hospital-by-hospital allocation is the detail most summaries drop, and it is the one that decides where you would actually travel.

Can foreigners get stem cell therapy in China?

The zone was built for medical travel, so a foreign passport is not the obstacle; the diagnosis is. Candidacy for any licensed cell technology is decided by the treating hospital's specialists after their own diagnostics, not by a booking, and the filed criteria apply to an international patient exactly as they apply to a domestic one. The practical sequence is records first, then a specialist reading of those records, then a decision. Hainan's 30-day visa-free entry covers the visit itself for most nationalities, which our visa guide sets out in detail.

How much does stem cell therapy cost in China?

There is no price list for the treatment programmes, and that is deliberate rather than evasive: a hospital quote is built from your own diagnostics, your staging and the course your specialists decide on. What does carry a published figure is the wellness side — the retreat is offered from about $2,700 all in for one guest, covering the four days, the screening battery, the wellness axes your screen selects and the follow-up year, against roughly $36,000 to $58,000 at 2026 rates for a comparable week at an Alpine longevity clinic. A treatment figure quoted to you before anyone has read your results is telling you about the seller rather than about the protocol.

Can you get stem cell therapy in China for anti-ageing?

No, and the reason is structural rather than a matter of policy at any one clinic. Every filed indication names a disease, and ageing is not a diagnosis, so there is no filing a hospital could deliver against. Stem cell programmes here are therefore paused for longevity-only use. If the screening finds something clinical, or you arrive with a prescription or diagnosis from your own physician, cell therapy proceeds on the ordinary clinical footing. The non-cell longevity programmes — oxygen, light, plasma exchange, functional infusion, the mitochondrial protocols — carry no such restriction, and they are where the wellness half of a stay actually lives.

Is stem cell therapy in China safe?

Safety inside the licensed frame is decided long before you arrive, in the manufacturing suite and in the exclusion criteria, and the licensed frame is the whole point of the distinction this page draws. A technology filed at the zone carries a defined product, a defined dose, a release specification and a named set of people it must not be given to. The risks that remain are real and mostly procedural rather than exotic, and our safety guide sets them out by mechanism along with who is declined and why that protects you. The genuinely unsafe version of this category is the one sold outside any filing at all.

What is the difference between stem cell therapy and immune cell therapy in China?

Stem cell therapy here means mesenchymal stem cells, usually from umbilical cord tissue, given for a structural or organ disease such as knee osteoarthritis or decompensated cirrhosis. Immune cell therapy means a patient's own immune cells — natural killer cells, dendritic cells — expanded and returned, almost always as an adjunct in cancer care rather than as a treatment on their own. The distinction matters when reading the zone's list, because four of the six technologies added in the fifth batch are immune cell products while the category noun most people search for is stem cell. Our NK cell therapy and immunotherapy guides cover each family properly.

What if my condition is not on the approved list?

Then there are three honest answers and one bad one. A registered clinical trial may be recruiting for it, which is a different legal route with its own consent and its own uncertainty. The zone's real-world pathway may make a licensed imported drug or device available for it even where no cell technology exists. Or the answer is simply no for now, which is the most common one and the one worth hearing clearly. The bad answer is a clinic — anywhere — offering the same cells for your condition with no filing behind them, on the argument that the cells are the same; the filing is what the regulation is about, and its absence is the warning.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.